



## **NZX Announcement**

**21 April 2020**

### **Truscreen expands to Vietnam with Ministry of Health Approval**

TruScreen Limited (NZX:TRU) (TruScreen or the “Company”) is pleased to advise that it has received approval from the Ministry of Health (MOH) of the Vietnam Government for the commercial roll out of the TruScreen cervical cancer screening device.

This landmark approval is granted initially for the Hanoi Obstetrics and Gynaecology Hospital (HOGH). It is anticipated that further rollouts across other public and private hospitals in Vietnam will occur this year.

The approval follows a MOH managed clinical trial covering 989 patients which was concluded successfully with a positive clinical outcome at the HOGH. The trial compared the specificity and sensitivity between the results from the TruScreen handheld real-time screening device and Pap test for the detection of cervical early stage pre-cancerous, and progressing intraepithelial lesions. The outcome of the trial was assessed by the Vietnam Ministry of Health Professional Advisory Committee which endorsed and approved the introduction of TruScreen cervical cancer screening technology in Vietnam.

TruScreen CEO, Victoria Potarina comments, *“The Vietnam government approval of TruScreen is a significant milestone for the Company. Together with our local distributor, Gorton Health Services we have been engaged on this project for over two years, in a review process that has been extremely thorough.*

*We look forward to working with HOGH and the MOH in improving the health and lives of women in Vietnam.”*

This announcement has been approved by the board.

- ENDS -

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

#### **TruScreen**

Victoria Potarina

Chief Executive Officer

[victoriapotarina@truscreen.com](mailto:victoriapotarina@truscreen.com)

Guy Robertson

Chief Financial Officer

[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

**About TruScreen:**

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at [www.truscreen.com](http://www.truscreen.com)

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>